The DOI matches its Crossref record; 159 of the 160 references it cites were found in a registry or an index.
Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients
Abstract
Benzodiazepines (BZDs; including the related Z-drugs) are frequently targets for deprescribing; long-term use in older people is harmful and often not beneficial. BZDs can result in significant harms, including falls, fractures, cognitive impairment, car crashes and a significant financial and legal burden to society. Deprescribing BZDs is problematic due to a complex interaction of drug, patient, physician and systematic barriers, including concern about a potentially distressing but rarely fatal withdrawal syndrome. Multiple studies have trialled interventions to deprescribe BZDs in older people and are discussed in this narrative review. Reported success rates of deprescribing BZD interventions range between 27 and 80%, and this variability can be attributed to heterogeneity of methodological approaches and limited generalisability to cognitively impaired patients. Interventions targeting the patient and/or carer include raising awareness (direct-to-consumer education, minimal interventions, and 'one-off' geriatrician counselling) and resourcing the patient (gradual dose reduction [GDR] with or without cognitive behavioural therapy, teaching relaxation techniques, and sleep hygiene). These are effective if the patient is motivated to cease and is not significantly cognitively impaired. Interventions targeted to physicians include prescribing interventions by audit, algorithm or medication review, and providing supervised GDR in combination with medication substitution. Pharmacists have less frequently been the targets for studies, but have key roles in several multifaceted interventions. Interventions are evaluated according to the Behaviour Change Wheel. Research supports trialling a stepwise approach in the cognitively intact older person, but having a low threshold to use less-consultative methods in patients with dementia. Several resources are available to support deprescribing of BZDs in clinical practice, including online protocols.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Issues related to switching to a longer-acting BZD are of particular concern in older adults, who may be at greater risk of medication-related harm because of age-related changes in pharmacokinetics and pharmacodynamics, such as reduced clearance of certain sedative–hypnotic medications and increased sensitivity to CNS effects.92,93”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“Older adults’ decreased hepatic metabolism changes how the body processes and responds to medications, causing them to stay in the body longer and increasing the risk of adverse effects.92,93”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“Fragmented care can be a barrier to effective BZD tapering because attitudes, knowledge, and conflicting advice from a patient’s medical teams (e.g., primary care, psychiatry, neurology, other specialty clinicians) and care partners can influence the BZD tapering process.92,169,170”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“metabolic changes associated with aging make older adults more sensitive to BZDs, increasing their risk of adverse events such as cognitive impairment, particularly in the domains of memory, learning, attention, and visuospatial ability.92,171,172”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [92]
In the citing paper
“The focus of BZD deprescribing, especially among older adults, has become more prominent in Western and European nations especially in recent years given an aging demographic trend and the known risks of these agents in this population.163,164”
Citations
Cites
1 retracted
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194.pub2 · Cited by 150 · cited 3×
“Medications trialled include switching to long half-life BZDs such as diazepam or lormetazepam [43, 96]; antidepressants such as paroxetine [95, 135], imipramine [136] and trazodone [96]; hypnotics such as melatonin [93, 137]; b-blockers; and antiepileptics such as carbamazepine [138] and pregabalin [139].”
BackgroundRetractedMichie, S., van Stralen, M. M., & West, R. (2011) · Implementation Science · doi:10.1186/1748-5908-6-42 · Cited by 13,697 · cited 3×
“We have considered the role of Michie’s Behaviour Change Wheel [86] and the Behaviour Change Techniques Taxonomy (BCTT) Version 1 [87] in describing the interventions, and, using published methods, a single T a b le 2 S u m m ar y o f se le ct ed in te rv en ti o n s ta rg et ed at p at ie n ts to ce as e b en zo d ia…”
BackgroundMethodHoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D. G., Barbour, V., Macdonald, H., Johnston, M., et al. (2014) · BMJ · doi:10.1136/bmj.g1687 · Cited by 10,548
Michie, S., Richardson, M., Johnston, M., Abraham, C., Francis, J., Hardeman, W., Eccles, M. P., Cane, J., & Wood, C. E. (2013) · Annals of Behavioral Medicine · doi:10.1007/s12160-013-9486-6 · Cited by 7,629 · cited 4×
“Applying the BCTT [87] to an example minimal intervention letter [42] identified techniques 5.1 (information relating to health consequences), 5.6 (information relating to emotional consequences) and 4.1 (instruction on how to perform a behaviour).”
MethodInfluentialEncyclopedia of human behavior
(1994) · Choice Reviews Online · doi:10.5860/choice.32-0638 · Cited by 3,234
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
STOPP/START criteria for potentially inappropriate prescribing in older people: version 2
O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2014) · Age and Ageing · doi:10.1093/ageing/afu145 · Cited by 2,397
Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005) · BMJ · doi:10.1136/bmj.38623.768588.47 · Cited by 1,161
Cumming, R. G., Salkeld, G., Thomas, M., & Szonyi, G. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.5.m299 · Cited by 896 · cited 1×
“Older people with low self-efficacy regarding falls prevention are prospectively associated with a higher risk of falling, lower functional activity, social participation and nursing home admission [56, 57].”
BackgroundReeve, E., Gnjidic, D., Long, J., & Hilmer, S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12732 · Cited by 855 · cited 1×
“Deprescribing is defined as ‘‘the withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes’’ [76].”
BackgroundSelf-citation
Research works printed but not linked: 3
- Hatton J. Fear of falling and its relationship to depression and anxiety in older adults living in the community and in extended care facilities in Australia [professional Doctorate]. Perth: Murdoch University; 2016.
- Petrovic M, Pevernagie D, Van Den Noortgate N, Mariman A, Michielsen W, Afschrift M. A program for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: Success rate and effect on subjective sleep quality. Int J Geriatr Psychiatry. 1999;14(9):754–60. · doi:10.1002/(sici)1099-1166(199909)14:9<754::aid-gps15>3.0.co;2-e
- Towle I, Adams J. A novel, pharmacist-led strategy to reduce the prescribing of benzodiazepines in Paisley. Pharm J. 2006;276(7386):136–8.
Cited by
Deprescribing in older adults with polypharmacy
Hung, A., Kim, Y. H., & Pavon, J. M. (2024) · BMJ · doi:10.1136/bmj-2023-074892 · Cited by 172
“38 39 Implementation strategies Overcoming these barriers is paramount for successful deprescribing, and implementation science can offer valuable tools and strategies.”
BackgroundBrandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
“163,164 Barriers and enablers of BZD deprescribing success are being increasingly understood from the exploration of the patient and pre-scriber experiences.”
BackgroundLynch, T., Ryan, C. A., Hughes, C. M., Presseau, J., van Allen, Z., Bradley, C., & Cadogan, C. A. (2020) · Addiction · doi:10.1111/add.14981 · Cited by 100
“This is concerning, as age-related physiological changes impact on the drugs’ pharmacokinetics and pharmacodynamics, therebymakingolder adults most susceptible to BZRAs’ adverse effects such as falls, fractures and cognitive impairment [21,22].”
BackgroundCapiau, A., Huys, L., van Poelgeest, E. P., van der Velde, N., Petrović, M., Somers, A., & the EuGMS Task, F. G. O. F. (2022) · European Geriatric Medicine · doi:10.1007/s41999-022-00731-4 · Cited by 93
“Deprescribing is challenging, because patients and physicians are often reluctant out of fear for the potential risk of the withdrawal syndrome [80].”
BackgroundTorres-Bondia, F., de Batlle, J., Galván, L., Buti, M., Barbé, F., & Piñol-Ripoll, G. (2020) · BMC Public Health · doi:10.1186/s12889-020-08984-z · Cited by 69
Metadata
- Authors
- Ng, B. J., Le Couteur, D. G., & Hilmer, S. N.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Hilmer, Sarah N.
- Venue
- Drugs & Aging
- Published
- 2018-04-28
- Volume
- 35
- Issue
- 6
- Pages
- 493-521
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- OpenAlex
- W2800093210
- Cited by
- 118
- References
- 160
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 13 · 2023: 14 · 2022: 23 · 2021: 22 · 2020: 11 · 2019: 14 · 2018: 2
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ageing and Alzheimers Institute
- Penney Ageing Research Unit
- New South Wales Health Translational Research Grants Scheme (TRG274)
- Australian and New Zealand Society for Geriatric Medicine
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepine deprescribing, older adults, Z-drugs, gradual dose reduction, cognitive behavioral therapy, sleep hygiene, prescribing interventions, pharmacist intervention, medication review, Behaviour Change Wheel, dementia, withdrawal syndrome, falls and fractures, cognitive impairment
- MeSH terms
- Deprescriptions, Age Factors, Attitude of Health Personnel, Benzodiazepines, Geriatrics, Humans, Pharmacists, Physicians, Drug Prescriptions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients. https://app.cochat.ai/papers/10.1007/s40266-018-0544-4
- The paper
- Ng, B. J., Le Couteur, D. G., & Hilmer, S. N. (2018). Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients. Drugs & Aging. https://doi.org/10.1007/s40266-018-0544-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.